In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis

Mehta, R.; Keyhani, Afsaneh; McQueen, T J; Rosenbaum, Beverly; Rolston, Kenneth V. I.; Tarrand, Jeffrey J.

doi:10.1128/aac.37.12.2584

Cited by 55 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The therapeutic activity of free and encapsulated INH and RIF was evaluated at both therapeutic and sub-therapeutic dose [47]. Parenteral clofazimine liposomes were [48] evaluated in acute and chronic murine infections [49]. Liposomes significantly reduced the toxicity of the drug both in vitro and in vivo and showed enhanced anti-TB activity in acute and chronic models.…”

Section: Drug Delivery Explored In Tb Chemotherapy Liposomesmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

Section: Drug Delivery Explored In Tb Chemotherapy Liposomesmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

show abstract

“…Overall, a significant increase in the anti-TB activity was found. With the aim of improving the anti-TB activity, reducing the toxicity and enabling the parenteral administration of highly lipophilic clofazimine, drug-loaded liposomes were produced [65] and preclinically evaluated in acute and chronic murine infections [66]. Encapsulation reduced the in vitro and in vivo toxicity of the drug and enhanced the anti-TB activity in both acute and chronic models.…”

Section: (B)nonpolymeric Nanocarrier Liposomementioning

confidence: 99%

Nanotechnology: A focus on Treatment of Tuberculosis.

Kumar¹,

Kumar²,

Kumar³

et al. 2011

Int J Drug Del

View full text Add to dashboard Cite

Despite the fact that we live in an era of advanced technology and innovation, infectious diseases, like Tuberculosis (TB), continue to be one of the greatest health challenges worldwide. The main drawbacks of conventional TB treatment are the development of multiple drug resistance, resulting in high dose requirements and subsequent intolerable toxicity. Therefore there is a need of a new system have been receiving special attention with the aim of minimizing the side effects of drug therapy, such as poor bioavailability and the selectivity of drugs. Nanoparticle-based drug delivery systems have considerable potential for treatment of TB. The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for TB.

show abstract

“…Elimination of mycobacterium from liver and spleen was found higher with liposomal drugs when compared with free drugs which offer more promising therapeutic approach for the chemotherapy of tuberculosis [31]. Clofazimine, Resorcinomycin A, and PD 117558 loaded liposome incorporated against several patients with microbial infection showed complete killing of bacteria at concentrations ranging from 8 to 31 µg/ml and thus liposomes, would help to reduce the toxicities of the drugs and could be used to target macrophages [32]. AMK encapsulated liposomes were found to be in high and sustained drug levels in infected tissues, exceeding the MIC for M. avium for at least 28 days while comparing with ciprofloxacin (CPF) encapsulated liposome in M. avium infected murine model.…”

Section: Liposomesmentioning

confidence: 99%

Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis

Cm¹,

Cd²,

M³

et al. 2017

J Nanosci Curr Res

View full text Add to dashboard Cite

Tuberculosis (TB) is an airborne infectious disease spreading very fast from person to person, which affect the health as well as socioeconomic conditions harshly. Though varieties of antitubercular drugs (ATDs) are available for its treatment, associated stern side effects restrict the patients to receive complete therapeutic benefits. Moreover, emergence of drug-resistant tuberculosis and co-infection of TB with HIV further worsen the situations. Polymeric formulations are introduced for progressive and long-term delivery of therapeutic agents, but owing to their noted limitations, performance is not up to the mark. In this juxtaposition, lipid based nano-formulations are introduced as an alternative to the polymic formulations in the management of TB with an intention to overcome side effects related to drugs along with limitations of polymeric formulations. The lipid based formulations comprise nanoemulsions, solid-lipid nanoparticles (SLNs), nano-structured lipid carriers (NLCs), liposomes, and niosomal systems, etc.Liposomes have more promising antitubercular activity as its intended for targeted drug delivery especially to the infected part. Further mannosylation of liposomes offers tremendous results in TB chemotherapy as it directly binds to mannose receptors available on the surface of alveolar macrophages resulting mycobacterium destruction. Niosomes may have superior drug targeting ability, chemical stability, osmotic activeness and in vivo activity in comparison to that of liposomes. SLNs and manosylated SLNs are the advanced form of the lipid formulations which enhance the drug uptake at the infected organ and show significant in vivo anti-tubercular activity with reduced toxicity. Moreover, NLCs shows its satisfactory potential against MTb along with drug targeting action. Advancement on the development of miscellaneous or other vesicular lipid formulations are not encouraging in the field of tubercular chemotherapy. Hence, lipid based formulations could be successfully employed for targeted delivery of ATDs with promising anti-tubercular activity.

show abstract

In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis

Cited by 55 publications

References 28 publications

Present status of nanoparticle research for treatment of Tuberculosis

Present status of nanoparticle research for treatment of Tuberculosis

Nanotechnology: A focus on Treatment of Tuberculosis.

Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis

Contact Info

Product

Resources

About